Physician profile
Benjamin N Levron
NPI 1184159501
$5,281.37
in general payments reported to CMS, 2019-2025
31 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $268 · 2021: $351 · 2022: $903 · 2023: $1,273 · 2024: $1,427 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,759.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,024.90 | 2020-2025 | |
| Lilly USA, LLC | $650.33 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $617.42 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $530.83 | 2021-2025 | Repatha, Otezla, Prolia |
| Gilead Sciences, INC. | $419.47 | 2022-2025 | Yeztugo |
| Takeda Pharmaceuticals U.S.A., INC. | $326.50 | 2021-2025 | Trintellix |
| Glaxosmithkline, LLC. | $269.82 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Ironwood Pharmaceuticals, INC | $165.67 | 2023 | Linzess |
| Astrazeneca Pharmaceuticals LP | $141.55 | 2022-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.17 | 2021-2024 | Jardiance, Synjardy |
| Abbott Laboratories | $103.61 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Axsome Therapeutics, INC. | $101.65 | 2024-2025 | Auvelity |
| Fujifilm Healthcare Americas Corporation | $100.33 | 2023 | Utaswako Afp-L3 |
| Pfizer INC. | $98.65 | 2021-2025 | |
| Viiv Healthcare Company | $75.58 | 2023-2024 | Apretude |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.12 | 2024-2025 | Caplyta |
| Allergan, INC. | $48.77 | 2020 | |
| Daiichi Sankyo INC. | $41.63 | 2022-2024 | Injectafer |
| Exact Sciences Corporation | $40.40 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $39.78 | 2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $35.29 | 2023-2024 | Rexulti, Abilify Asimtufii, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $34.31 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $33.43 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $32.15 | 2021 | |
| Shield Therapeutics INC | $31.61 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $31.42 | 2024 | |
| Hologic Sales and Service, LLC | $25.98 | 2023 | Affirm Prone Biopsy System |
| Astellas Pharma US INC | $20.83 | 2024 | Veozah |
| Lundbeck LLC | $19.26 | 2024 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $16.93 | 2022 | |
| Merck Sharp & Dohme LLC | $11.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Levron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.